68Ga-FAPI-04 PET-CT for molecular assessment of fibroblast activation and risk evaluation in systemic sclerosis-associated interstitial lung disease: a single-centre, pilot study
Lung disease is the most common cause of death in systemic sclerosis. It is judged by the accrual of lung damage on CT and pulmonary function tests. The antifibrotic drug nintedanib might improve risk assessment. The study is the first-in-human evidence that fibroblast activation correlates with disease progression in the lungs of patients with MS.